B-cell subpopulations and clinical characteristics
Parameter . | Scleroderma . | Bronchiolitis obliteraus . | Mild/moderate vs severe . | ≤ 2 vs > 2 organs involved . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Yes . | No . | P . | Yes . | No . | P . | Mild/moderate . | Severe . | P . | ≤ 2 . | > 2 . | P . | |
CD19+ B cells × 106/L | 302 | 453 | .06 | 258 | 428 | .041* | 420 | 207 | .07 | 405 | 227 | .019* |
Immature B cells absolute × 106/L | 26 | 28 | .74 | 25 | 28 | .57 | 26 | 26 | .7 | 31 | 23 | .8 |
% | 14.1 | 7.7 | .02* | 16.1 | 8.04 | .002* | 9.2 | 14.5 | .54 | 9.2 | 5.7 | .07 |
Transitional B cells absolute × 106/L | 26 | 23 | .78 | 11 | 23 | .25 | 19 | 18 | .6 | 22 | 15 | .3 |
% | 7.2 | 4.1 | .18 | 4 | 6.2 | .38 | 7.2 | 7 | .48 | 6.1 | 3.6 | .15 |
Naive B cells absolute × 106/L | 270 | 380 | .2 | 200 | 360 | .05 | 360 | 170 | .07 | 340 | 170 | .03* |
% | 84 | 84 | .9 | 77 | 85 | .0089* | 86 | 79 | .012* | 85 | 83 | .58 |
Class-switched memory B cells absolute × 106/L | 10 | 40 | .005* | 25 | 30 | .6 | 26 | 11 | .44 | 30 | 10 | .038* |
% | 6.1 | 8 | .28 | 9 | 7.6 | .41 | 6.3 | 7.8 | .03* | 6.3 | 7.9 | .55 |
Non–class-switched memory B cells absolute × 106/L | 7 | 10 | .037* | 4 | 10 | .017* | 10 | 4 | .0096* | 10 | 5 | .022* |
% | 3.01 | 3.15 | .85 | 2.7 | 2.9 | .83 | 3.2 | 2.4 | .17 | 3.1 | 2.3 | .28 |
BAFF, ng/mL | 1.7 | 0.76 | .0001* | 2.3 | 1.1 | .04* | 1.78 | 1.9 | .39 | 1.6 | 0.8 | .18 |
IgG, mg/dL | 1955 | 1124 | .001* | 1168 | 1113 | .82 | 1396 | 1108 | .65 | 1324 | 1106 | .17 |
Ratio BAFF/immature B cells | 0.09 | 0.05 | .01* | 0.12 | 0.07 | .09 | 0.01 | 0.02 | .9 | 0.12 | 0.06 | .4 |
Ratio BAFF/memory B cells | 0.17 | 0.04 | .02* | 0.24 | 0.12 | .4 | 0.12 | 0.15 | .86 | 0.18 | 0.04 | .33 |
Ratio BAFF/CD19+ B cells | 0.01 | 0.004 | .08 | 0.01 | 0.0063 | .03* | 0.21 | 0.23 | .4 | 0.01 | 0.002 | .5 |
Parameter . | Scleroderma . | Bronchiolitis obliteraus . | Mild/moderate vs severe . | ≤ 2 vs > 2 organs involved . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Yes . | No . | P . | Yes . | No . | P . | Mild/moderate . | Severe . | P . | ≤ 2 . | > 2 . | P . | |
CD19+ B cells × 106/L | 302 | 453 | .06 | 258 | 428 | .041* | 420 | 207 | .07 | 405 | 227 | .019* |
Immature B cells absolute × 106/L | 26 | 28 | .74 | 25 | 28 | .57 | 26 | 26 | .7 | 31 | 23 | .8 |
% | 14.1 | 7.7 | .02* | 16.1 | 8.04 | .002* | 9.2 | 14.5 | .54 | 9.2 | 5.7 | .07 |
Transitional B cells absolute × 106/L | 26 | 23 | .78 | 11 | 23 | .25 | 19 | 18 | .6 | 22 | 15 | .3 |
% | 7.2 | 4.1 | .18 | 4 | 6.2 | .38 | 7.2 | 7 | .48 | 6.1 | 3.6 | .15 |
Naive B cells absolute × 106/L | 270 | 380 | .2 | 200 | 360 | .05 | 360 | 170 | .07 | 340 | 170 | .03* |
% | 84 | 84 | .9 | 77 | 85 | .0089* | 86 | 79 | .012* | 85 | 83 | .58 |
Class-switched memory B cells absolute × 106/L | 10 | 40 | .005* | 25 | 30 | .6 | 26 | 11 | .44 | 30 | 10 | .038* |
% | 6.1 | 8 | .28 | 9 | 7.6 | .41 | 6.3 | 7.8 | .03* | 6.3 | 7.9 | .55 |
Non–class-switched memory B cells absolute × 106/L | 7 | 10 | .037* | 4 | 10 | .017* | 10 | 4 | .0096* | 10 | 5 | .022* |
% | 3.01 | 3.15 | .85 | 2.7 | 2.9 | .83 | 3.2 | 2.4 | .17 | 3.1 | 2.3 | .28 |
BAFF, ng/mL | 1.7 | 0.76 | .0001* | 2.3 | 1.1 | .04* | 1.78 | 1.9 | .39 | 1.6 | 0.8 | .18 |
IgG, mg/dL | 1955 | 1124 | .001* | 1168 | 1113 | .82 | 1396 | 1108 | .65 | 1324 | 1106 | .17 |
Ratio BAFF/immature B cells | 0.09 | 0.05 | .01* | 0.12 | 0.07 | .09 | 0.01 | 0.02 | .9 | 0.12 | 0.06 | .4 |
Ratio BAFF/memory B cells | 0.17 | 0.04 | .02* | 0.24 | 0.12 | .4 | 0.12 | 0.15 | .86 | 0.18 | 0.04 | .33 |
Ratio BAFF/CD19+ B cells | 0.01 | 0.004 | .08 | 0.01 | 0.0063 | .03* | 0.21 | 0.23 | .4 | 0.01 | 0.002 | .5 |
Significant P value.